Announcement event for the first beneficiaries of the messenger RNA vaccine technology transfer center.

France Emmanuel Macron · President of France

18 February 2022 · Announcement event for the first beneficiaries of the messenger RNA vaccine technology transfer center

Context
Macron addressed the announcement event for the first beneficiaries of the WHO mRNA vaccine technology transfer hub, held on February 18, 2022.
Main themes
MRNA vaccine technology transfer, Africa-Europe cooperation, vaccine sovereignty for Africa, intellectual property and compulsory licenses, COVID-19 pandemic response, technology hubs in African nations, dose donations and vaccination, pharmaceutical production capacity, ACT-A initiative, French and EU funding commitments
Duration
~8 min
29th percentile
Words
1,009
29th percentile
Sentences
50
33rd percentile
Readability
54
74th percentile
Grade
10.7
29th percentile
Syntax
2.76
18th percentile
Vocabulary
2.02
13th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 51%50%
  • Social 18%18%
  • Ceremonial 16%16%
  • Geopolitical 14%14%
  • Technological 0%0%
  • Environmental 0%0%
  • Institutional 0%0%
  • Not in focus 2%

50 sentences in 9 paragraphs

Ladies and gentlemen, presidents,

Ladies and gentlemen,

Everything has been said, and I will get straight to the point. This crisis has provided an unprecedented opportunity for cooperation between Africa and Europe. As early as spring 2020, it was between the African Union and the European Union that we built the ACT-A initiative. We then convinced the other G20 members. Through this initiative, we were able to deploy unprecedented cooperation to export, provide doses, deliver test kits, and support primary health systems, which, it must be said, we had sometimes abandoned over the past decades. The results have been there, and I want to emphasize how present Europe has been; I recalled the figures yesterday, producing more and more and exporting and giving much more than all the other powers, even at the peak of the crisis.

The second step is obviously to build the means for the African continent to be more sovereign. And this sovereignty agenda, which I believe in for Europe, I believe in the same way for Africa within the framework of a fair partnership. We know the figures. We were together last May with President RAMAPHOSA on this subject to launch the beginnings of this hub. The African continent does not simply want, as he reminded us, to be given doses, to have them transferred. It wants to be able to produce them on its own soil. And a month later, Dr. TEDROS, dear President, you launched this initiative that is materializing today. So, I really want to first congratulate the six presidents of the African continent present here for their commitment and mobilization, as they will have these antennas of the mRNA technology transfer hub on their soil.

Next, I want to thank the entire European Commission and the partner European countries; France will contribute 20 million euros to our funding, and you can count on the mobilization, of course, of our experts from the French Development Agency, and I think we also have a tremendous opportunity for new cooperation between South African academics for the first hub, as has been mentioned, with Afrigen, industrialists, Biovac, soon Sanofi Pasteur, the World Health Organization, European funding, and the Medicines Patent Pool. I really want to commend the work of the teams, especially Marie-Paule KIENY, who has done a tremendous job without whom this project could not take place.

Because we need to be very clear in the short term, what would prevent production, I say this very clearly, is not the issue of intellectual property. It is the issue of technology transfer. It is about having the experts who will run the factories. Even before asking where the money goes, it is about developing these capacities that many European countries do not yet have. So, we are doing things in the right order. We have made donations of doses, done everything to help with vaccination. We must continue. Now, we are launching these technology transfer hubs because it is the key to developing the factories and production capacities for mRNA vaccines. And so, we need to go all in, and now, we need, President VON DER LEYEN is right, the best cooperation from all the industrialists who are committed, and they need to transfer the know-how, including the most confidential, so that in these six regional centers, we can produce as quickly as possible.

Then, we need to have commitments for purchases, local purchases, but also international purchases, and I think that in the long term, the point raised by President RAMAPHOSA is very important, meaning that we cannot explain that we will continue to buy doses elsewhere that are meant for the African continent. These local production centers must become a priority.

And then, we have the question of intellectual property on which I hope the discussions this morning will allow us to make progress. I think the goal we must pursue is that intellectual property should never be a barrier to the production and distribution of vaccines wherever they are needed. That is the goal. And so, we know the issue. I expressed my position when I was in South Africa; it has not changed. We can absolutely move forward on this. Now, I say this even more easily, you often hear me repeat this phrase, that there are no French industrialists involved. So, I have the easy role, but we must be consistent with everyone. We must protect intellectual property because it is very important for us to continue to create, innovate, and invent; we must respect that. Intellectual property must never be a hindrance to the dissemination of knowledge and the building of these capacities. That is the way forward. And I think the idea of compulsory licenses that the President mentioned, the proposals that the World Health Organization is working on with the World Trade Organization are relevant paths, and above all, we must now be able to conclude.

But here is what I wanted to summarize. We have succeeded together on the donation of doses. We are succeeding in technology transfer, production with the hubs, and you can count on our mobilization, the transfer of talents, and funding. And we must succeed in the long term to ensure that intellectual property is never a barrier to solidarity and access for all peoples, particularly those of the African continent, to vaccines and innovation. Because beyond the battle against Covid-19, we have the battle against all the pandemics that cross the African continent. I was with several of you a few years ago to complete the Global Fund and try to make progress on these pandemics. We must not lose sight of the fact that even if we manage to overcome Covid, and I hope sooner rather than later, the African continent still has many pathologies today that we could overcome with more vaccination and many pathologies that we must be able to overcome in the coming years thanks to new vaccines. And so, the fight we are waging today is also a fight for tomorrow, beyond Covid-19. Thank you.